Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

COVID-19 vaccine doses could arrive in Canada early in 2021 -minister

Published 2020-09-10, 03:41 p/m
PFE
-
NVAX
-
MRNA
-

TORONTO, Sept 10 (Reuters) - Canada is "aggressively negotiating" with drugmakers on delivery schedules for potential COVID-19 vaccines and shipments would begin early in 2021 under existing deals, Canada's minister of public services and procurement told Reuters on Thursday.

The Canadian government has announced four vaccine purchase deals and is negotiating more, while also funding local projects that are less advanced, and building new vaccine manufacturing capacity at a facility in Montreal. exact timing of deliveries depends on the result of clinical trials, regulatory approvals and manufacturing capacity, the minister, Anita Anand, said. Should approvals come earlier than expected, the government will negotiate earlier deliveries, she added.

"Make no mistake, suppliers are reserving manufacturing capacity to supply doses to Canada based on those aggressively negotiated delivery schedules," Anand said in a phone interview.

Canada has agreements with vaccine makers Moderna Inc MRNA.O , Pfizer Inc (NYSE:PFE) PFE.N , Novavax Inc NVAX.O and Johnson & Johnson JNJ.N . Anand did not say which company was scheduled to deliver first, but the Pfizer and Moderna vaccine candidates are among the most advanced.

Late stage trials from Pfizer and Moderna involving about 30,000 subjects each are on track to be fully enrolled soon. Pfizer has said that a first analysis of their data could be available as soon as October.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.